Stock Ratings / Health Care / HBIO / financials

RPID (47) PRPO (38) EYPT (38) BNGO (36) ⌘ Pro Terminal →

Harvard Bioscience Inc. (HBIO) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$8.80 +4.51% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Harvard Bioscience Inc. (HBIO) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $40.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-6.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HBIO)Realized 20D OHLCV Swing Band: ±8.8%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How HBIO Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$5.5M (6.3% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $112.3M

FY24

Rev $94.1M

FY25

Rev $86.5M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$86.5M	57.7%	-56.1%	-$56.7M	$5.5M	-45%
FY 2024	$94.1M	58.2%	-6.6%	-$12.4M	-$1.2M	-8.3%
FY 2023	$112.3M	57.7%	1.7%	-$3.4M	$14.0M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HBIO)

✓Walkthrough of HBIO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HBIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +37.93%⚡ TESTING RESISTANCE

2026-10-30O $8.80H $8.92L $8.71C $8.80VOL 23.2K

RES: $9.06SUP: $6.24SMA50: $8.12SMA200: $6.44

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HBIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HBIO Butterfly Map → + Track HBIO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -8.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HBIO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HBIO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HBIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HBIO)

Health Care Rank #520 of 1016 ⚔️ RPID vs HBIO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HBIO vs. RPID, PRPO, EYPT, BNGO)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Harvard Bioscience Inc. (HBIO) ranks #520 by composite RQD confidence (44/100, grade D) and #775 by equity capitalization ($40.1M). Within this direct 5-issuer industry benchmark cohort, HBIO leads on earnings valuation at N/A trailing P/E, while PRPO leads on capital efficiency and profitability with -7.9% ROIC and 44.2% gross margin. RPID currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with HBIO at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HBIO ACTIVE Harvard Bioscience Inc.	D	44/100	—	57.7%	-35.0%	+4.51%	$40.1M	Benchmark Subject
RPID Rapid Micro Biosystems Inc. (Class A)	D	47/100	—	—	-35.0%	-1.37%	$39.6M	/rpid-vs-hbio →
PRPO Precipio Inc.	D-	38/100	—	44.2%	-7.9%	+3.59%	$34.6M	/prpo-vs-hbio →
EYPT EyePoint Inc.	D-	38/100	—	—	-35.0%	+0.69%	$32.8M	/eypt-vs-hbio →
BNGO Bionano Genomics Inc.	D-	36/100	—	46.3%	-35.0%	-0.41%	$16.8M	/bngo-vs-hbio →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001123494

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Harvard Bioscience Inc. (HBIO) reported GAAP revenue of $86.5M (-8.1% vs. FY2024 revenue of $94.1M , and -22.9% cumulative change since FY2023) , GAAP net income of -$56.7M, operating cash flow of $6.7M, and free cash flow of $5.5M (+554.4% YoY). On the balance sheet, HBIO closed FY2025 with $80.1M in total assets against $35.9M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$86.5M	-$56.7M	$6.7M	$5.5M	$80.1M	$35.9M
FY2024 (FY)	2024-12-31	$94.1M	-$12.4M	$1.4M	-$1.2M	$126.6M	$0
FY2023 (FY)	2023-12-31	$112.3M	-$3.4M	$14.0M	$14.0M	—	—

3. HBIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Harvard Bioscience Inc. (NASDAQ: HBIO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $8.80 (+4.51% 1D, market cap $40.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, HBIO ranks #520 in composite RQD confidence.

How does HBIO compare to RPID and PRPO in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), HBIO carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 57.7%, and ROIC of -35.0%. By comparison, RPID (Rapid Micro Biosystems Inc. (Class A)) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $39.6M) and PRPO (Precipio Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -7.9%, cap $34.6M). Among the 5-stock peer group, HBIO leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HBIO?

Per HBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001123494), Harvard Bioscience Inc. generated $86.5M in revenue (-8.1% YoY), -$56.7M in net income, and $5.5M in free cash flow against $80.1M in total assets and $35.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HBIO trading relative to its 50-day, 200-day, and 52-week technical levels?

HBIO last traded at $8.80 (+4.51% on volume of 50,009 shares), positioning the stock +8.37% above its 50-day simple moving average ($8.12) and +36.65% above its 200-day simple moving average ($6.44). Across its 52-week range of $4.00 to $9.00, HBIO sits at the 96.0% percentile with a 14-day RSI of 68.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±8.8% ($8.03 to $9.57).